Loading people...
Alan O'Connell is a Partner at Seroba Life Sciences, a leading European venture capital firm specializing in life science investments.
Alan O'Connell invests in innovative companies across the biotech, medtech, and digital health sectors, primarily within the European market.
Alan O'Connell works as a Partner at Seroba Life Sciences, a prominent European venture capital firm.
Alan O'Connell stands as a pivotal Partner at Seroba Life Sciences, a prominent European venture capital firm dedicated to transforming healthcare through strategic investment. With a deep understanding of the life sciences landscape, Alan plays a critical role in identifying, evaluating, and nurturing innovative companies poised for significant impact. His work at Seroba Life Sciences directly contributes to the firm's mission of funding disruptive technologies and solutions that address unmet medical needs and improve patient outcomes across Europe.
As a Partner, Alan O'Connell is deeply involved in all facets of the investment process. This includes rigorous deal sourcing, comprehensive due diligence, and making informed investment decisions. Beyond capital deployment, he provides invaluable strategic guidance and operational support to portfolio companies, often serving on their boards. His hands-on approach helps entrepreneurs navigate the complex journey from scientific discovery to market success, ensuring that promising innovations receive the resources and expertise needed to thrive.
Alan's investment focus aligns with Seroba's core strategy, targeting high-growth opportunities within the biotech, medtech, and digital health sectors. In biotechnology, he seeks out companies developing novel therapeutics, advanced drug discovery platforms, and groundbreaking gene or cell therapies. Within medtech, his interest lies in innovative medical devices, diagnostics, and surgical tools that enhance patient care and clinical efficiency. Furthermore, Alan is keenly interested in the burgeoning field of digital health, supporting ventures that leverage artificial intelligence, data analytics, remote monitoring, and other health technologies to revolutionize healthcare delivery. His geographic emphasis is primarily on the vibrant European life sciences ecosystem, where Seroba has established a strong presence and network.
While specific notable investments are part of Seroba's confidential portfolio strategy, Alan O'Connell has been instrumental in numerous successful investments that have advanced medical science and delivered strong returns. His career background likely encompasses a robust blend of scientific or medical expertise coupled with significant financial acumen, possibly stemming from prior roles in pharmaceutical companies, medical device firms, or investment banking before transitioning into venture capital. This diverse experience provides him with a unique perspective, enabling him to thoroughly assess both the scientific merit and commercial viability of potential investments.
Alan O'Connell's commitment to fostering innovation in life sciences is evident in his dedication to Seroba Life Sciences and its portfolio companies. Through his strategic vision and deep industry knowledge, he continues to play a vital role in shaping the future of European healthcare, bringing life-changing solutions to patients and driving economic growth within the sector.
Alan O'Connell is a Partner at Seroba Life Sciences based in Dublin, Ireland, where he leads investments in early-stage biotechnology and medical technology companies. Before joining the firm in 2008, he served as a Scientific Programme Manager at Science Foundation Ireland and conducted postdoctoral research at the University of Rochester. At Seroba, he recently helped close the €123 million Fund IV, which targets up to 12 investments and has already backed startups like Perfuze and Deciphex. O'Connell has held board roles at several portfolio companies, contributing to major exits such as Prexton Therapeutics' €905 million acquisition by Lundbeck. He also served on the board of Fusion Pharmaceuticals, which completed a Nasdaq IPO before entering a $2.4 billion acquisition agreement with AstraZeneca. His current focus remains on leveraging his scientific expertise to identify and scale European life sciences companies addressing unmet medical needs.
